Volrustomig Priming Regimens Exploratory Phase II Platform Study

Recruiting now · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Key facts

Study ID

NCT06448754

Run by

AstraZeneca

People needed

180

Starts

2024-08-27

Expected to finish

2027-07-30

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Genoa, Italy (enrolling)
• Research Site — Naples, Italy (enrolling)
• Research Site — Piraeus, Greece (enrolling)
• Research Site — Thessaloniki, Greece (enrolling)
• Research Site — Meldola, Italy (enrolling)
• Research Site — Milan, Italy (enrolling)
• Research Site — Elaiones, Greece (enrolling)
• Research Site — Beijing, China (enrolling)
• Research Site — Hangzhou, China (enrolling)
• Research Site — Jinan, China (enrolling)
• Research Site — Yantai, China (enrolling)
• Research Site — Zhengzhou, China (enrolling)
• Research Site — Bois-Guillaume, France (enrolling)
• Research Site — Caen, France (enrolling)
• Research Site — Athens, Greece (enrolling)
• Research Site — Dijon, France (enrolling)
• Research Site — Montpellier, France (enrolling)
• Research Site — Batumi, Georgia (enrolling)
• Research Site — Tbilisi, Georgia (enrolling)
• Research Site — Tbilisi, Georgia (enrolling)
• Research Site — Tbilisi, Georgia (enrolling)
• Research Site — Tbilisi, Georgia (enrolling)
• Research Site — Tbilisi, Georgia (enrolling)
• Research Site — Athens, Greece (enrolling)
• Research Site — Orbassano, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.